These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25984534)

  • 21. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
    Rasche L; Strifler S; Duell J; Rosenwald A; Buck A; Maeder U; Einsele H; Knop S
    Ann Hematol; 2014 Jul; 93(7):1207-14. PubMed ID: 24526137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
    Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
    Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
    Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
    J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
    Schilling G; Hansen T; Shimoni A; Zabelina T; Pérez-Simón JA; Gutierrez NC; Bethge W; Liebisch P; Schwerdtfeger R; Bornhäuser M; Otterstetter S; Penas EM; Dierlamm J; Ayuk F; Atanackovic D; Bacher U; Bokemeyer C; Zander A; San Miguel J; Nagler A; Kröger N
    Leukemia; 2008 Jun; 22(6):1250-5. PubMed ID: 18418408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
    Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
    Weinstock M; Aljawai Y; Morgan EA; Laubach J; Gannon M; Roccaro AM; Varga C; Mitsiades CS; Paba-Prada C; Schlossman R; Munshi N; Anderson KC; Richardson PP; Weller E; Ghobrial IM
    Br J Haematol; 2015 Jun; 169(6):851-8. PubMed ID: 25833301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytogenetic study on 53 patients with multiple myeloma].
    Jing Y; Fang MY; Jiang F; Lin S; Wang FT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):68-72. PubMed ID: 21362224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.
    Ji J; Guo R; Ma J; Cui Y; Li Y; Sun Z; Li J; Fan L; Qu X
    Clin Chim Acta; 2023 Aug; 548():117497. PubMed ID: 37479009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
    Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
    Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
    Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
    Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
    Jakubowiak AJ; Siegel DS; Martin T; Wang M; Vij R; Lonial S; Trudel S; Kukreti V; Bahlis N; Alsina M; Chanan-Khan A; Buadi F; Reu FJ; Somlo G; Zonder J; Song K; Stewart AK; Stadtmauer E; Harrison BL; Wong AF; Orlowski RZ; Jagannath S
    Leukemia; 2013 Dec; 27(12):2351-6. PubMed ID: 23670297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma.
    Hillengass J; Zechmann CM; Nadler A; Hose D; Cremer FW; Jauch A; Heiss C; Benner A; Ho AD; Bartram CR; Kauczor HU; Delorme S; Goldschmidt H; Moehler TM
    Int J Cancer; 2008 Jun; 122(12):2871-5. PubMed ID: 18351576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
    An G; Acharya C; Deng S; Yi S; Xu Y; Qin X; Sui W; Li Z; Shi L; Zang M; Feng X; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Tai YT; Qiu L
    Exp Hematol; 2015 Mar; 43(3):168-176.e2. PubMed ID: 25462022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias.
    Janjetovic S; Lohneis P; Nogai A; Balci D; Rasche L; Jähne D; Bokemeyer C; Schilling G; Blau IW; Schmidt-Hieber M
    Biology (Basel); 2021 Jul; 10(7):. PubMed ID: 34356484
    [No Abstract]   [Full Text] [Related]  

  • 39. MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma.
    Song Y; Du J; Jin X; Li H; Jia C; Liu Y; Li K; Zhou D; Zhuang J
    Eur J Haematol; 2024 Dec; 113(6):824-832. PubMed ID: 39191670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.